Welcome to Medications.com

Eisai issuer rating cut to 'A2' on higher leverage post MGI Pharma ... - Forbes

Meanwhile, the rating outlook is stable, reflecting Moody's view that Eisai's financial performance will continue to be strong, due to Aricept's sales ...

http://www.forbes.com/markets/fee... | Posted: Wed Mar 05 02:44:11 -0500 2008




© 2002-2007, Skylabs Inc.  |  About Us  |  Disclaimer/Terms of Use  |  Advertise  |  Contact Us  |  Site Map  |  Developed by: W3matter.com | Sleep Apnea